Pane wikiwiki
Zinc biology in hepatitis-targeting peptide development: a framework for uptake assay design, zinc control arms, and interpreting internalization data.
He aha ka Zinc Biology i ka Hepatitis-Targeting Peptide Development Real Reframes
ʻAʻole ʻo Zinc biology i ka hoʻomohala ʻana i ka peptide e pili ana i ka maʻi hepatitis i kahi papa kuhikuhi hou. He ʻano hoʻololi i lawe ʻia e kāu assay uptake a aneane ʻaʻole hōʻike: ʻo ke kūlana co-factor metala o nā pūnaewele a me ke kikowaena a lākou e noho ai.

ʻO ka ʻokoʻa ka mea nui ma waena o ka zinc iona a me ka zinc-manamana lima nā polokina. ʻO nā kāʻei kapu Zinc-finger he mau mea hoʻolalelale i hoʻopaʻa ʻia i ka DNA a i ʻole RNA; he kaawale ka ion zinc, ʻano hoʻololi i hoʻonohonoho ʻia e ka buffering. ʻO ka hoʻopili ʻana i nā mea ʻelua ka hewa maʻamau i kēia palapala, a hūnā ia i ka hoʻololi hoʻohālikelike.
Nui kēlā ʻano hoʻololi. Kuokoa, noho ʻo labile intracellular Zn²⁺ i loko o ka pae picomolar-a-haʻahaʻa-nanomolar ʻoiai e holo ʻokoʻa ka zinc cellular. 0.1 i 1.0 mM, kahi āwāwa ma kahi o ʻeono mau kauoha o ka nui (Krężel & Malaki, Nā waihona o Biochemistry a me Biophysics, 2016). Aia kahi waiwai cytosolic hoʻomaha calibrated kokoke 80 ± 7 pM (PNAS, 2011). Metallothionein, ka mea e nakinaki ana i ehiku Zn²⁺ no ka mole, me ZIP (SLC39A) a me ZnT (SLC30A) nā mea halihali, hoʻonohonoho i ka nui a me ka wahi o kēlā pool labile (Malaki, Nā holomua i ka meaʻai, 2013).
He kekona kāu waena, pale kūʻokoʻa. RPMI maʻamau 1640 ʻaʻole lawe i nā metala metala i hoʻohui ʻia; Nā papa inoa DMEM/F-12 1.5 nM zinc; RPMI 1640 me 10% Nā ana FCS 3.8 µM ka nui o ka zinc ma ka lawe ʻana i ka atomic, ʻoiai ʻo DMEM me 5% Hōʻike wale ʻo FCS e pili ana 259 pM manuahi Zn²⁺ (Sigma-Aldrich, 2024). ʻAʻole ʻo ka zinc o kāu medium ka zinc o kāu mau cell.
ʻO ka hopena kūpono he pilikia hoʻohālikelike. Inā haʻalele ka hoʻonohonoho ʻokoʻa i hōʻike ʻia, ka nui o ka serum a me ka hoʻoponopono zinc intracellular, hiki i ʻelua labs ke holo i ka peptide like a hoʻopuka i nā helu internalization ʻaʻole i ana ʻia ma lalo o nā kūlana like.
No ke aha e noho ai ʻo Zinc i loko o ka Peptide Uptake Assay inā ʻoe e hōʻike a ʻaʻole paha
Kakaʻikahi ka hana ʻana o ka peptide uptake assay design i ka zinc ma ke ʻano he loli, akā naʻe, hāʻawi ka mea waena a hoʻopaʻa ke kelepona iā ia. RPMI 1640 ua hoʻokumu ʻia me 0 µM hoʻohui i ka zinc, Nā papa inoa DMEM/F-12 1.5 nM, RPMI hoʻohui 10% nā ana serum keiki bipi hānai 3.8 µM ka nui o ka zinc, a me DMEM hoʻohui 5% lau serum ma kahi kokoke 259 pM manuahi (Sigma-Aldrich, 2024). No laila ke holo nei kēlā me kēia hoʻokolohua internalization ma kahi hoʻonohonoho zinc, i kapa ʻia nā ʻano hana i hoʻokahi a i ʻole.
ʻAʻole inert kēlā setpoint. Ma nā pūnaewele HeLa, zinc extracellular ma 10 i 40 Hoʻonui ka µM ZnCl₂ i ka ʻauʻau labile intracellular a pili pū me ka hoʻoulu ʻana o ERK a me Akt. (PNAS, 2021). ʻO kahi peptide e hoʻopaʻa ai a lawe i ka zinc e hoʻololi i ka loko i hilinaʻi ʻia ka heluhelu ʻana, no laila peptide:Aia ka Zn stoichiometry a me ke kūlana zinc medium i nā ala e pili ana i ka noʻonoʻo a me ka manawa.
Ki Takeaway: ʻOkoʻa nā kiʻi o kēia ʻano ma ke kumu, a ʻo nā kumu kūʻai waena a me nā serum ma luna nei he hoʻokumu- a me ka hailona. E hōʻike i ke kūlana zinc i ana ʻia o kāu ʻōnaehana ponoʻī ma mua o ka manaʻo ʻana i kahi waiwai catalog.
ʻO ka Hierarchy Heluhelu Mokuʻāina ʻEkolu no ka ʻikepili Hoʻokomo Peptide
ʻAʻole pinepine ka wehewehe ʻana i ka ʻikepili internalization peptide no ka mea ua noi ʻia kahi helu hoʻokahi e wehewehe i ʻekolu mau kūlana kino. Paʻa ʻili, ʻokoʻa ka hoʻopaʻa ʻana i ka endosomal a me ka cytosolic access, a ʻo ka hapa nui o nā hoʻokolohua e hōʻike i kahi hui ʻana o nā mea ʻekolu me ka ʻole o ka ʻōlelo ʻana pēlā.
ʻO Fixation ka mea hewa i kākau ʻia. ʻO Richard et al. (2003), loiloi ʻia ma Nā ʻano hana kūloko o nā peptides komo i loko o ke kelepona (2020), hōʻike i ka hoʻoponopono hou ʻana i ka peptide paʻa i ka membrane a ʻaʻole hiki i ka cytometry kahe ke hoʻokaʻawale i ka membrane-paʻa mai ka peptide i loko.. ʻO kēlā palena hoʻokahi e wehewehe i ke kumu e hiki ai i nā labs ʻelua ke hōʻike i nā hopena uptake kūʻē mai ke kaʻina like.
ʻAʻole paʻa ke ala ponoʻī. Ka mea like 2020 hōʻike hōʻike e pili ana ka lawe ʻana: ʻO ka endocytosis ka mana ma ka haʻahaʻa o ka peptide a me ka unuhi pololei ma ke kiʻekiʻe, ʻoiai ʻo penetratin e hoʻohuli i ke kānāwai. No laila, ʻo ka heluhelu ʻana i lawe ʻia ma ka noʻonoʻo ʻana i hoʻokahi ala, ʻaʻole ka peptide.
|
Hoʻāʻo |
Moku'āina e hōʻike maoli ana |
Confounder hiki ole ke ike |
|---|---|---|
|
Cytometry kahe, pūnaewele paʻa |
Paʻa ʻili + i loko, pāʻina |
Mea hana paʻa; ʻO ka peptide i hoʻopaʻa ʻia me ka membrane i helu ʻia ma ke ʻano he uptake |
|
ʻO ke kiʻi confocal pūnaewele ola |
Hoʻohui Peptide Māhele Paʻa Paʻa i ka ʻili vs i loko, hoʻoholo ākea |
Nā Manaʻo Hoʻohana Heluhelu ʻia ʻo Endosomal trapping ma ke ʻano he cytosolic access |
|
ʻO Cytosolic reporter a i ʻole ka hana hana |
Cytosolic komo wale |
Nalo o ka ʻili a me ka hōʻailona endosomal |
ʻAʻole kēia he peptide-specific failure mode. kanaka kuokoa, Ua hōʻike ʻia ʻo Venugopalan a me Withers ma PLOS Biology (2015) ʻoi aku ma mua o 50% ʻaʻole hiki ke hana hou ʻia ka noiʻi preclinical, ma kahi o US $28B i kēlā me kēia makahiki ma US wale nō, a ʻo Begley lāua ʻo Ellis i ʻike i kēlā wale nō 11% o nā palapala maʻi maʻi maʻi preclinical (6 o 53) hiki ke hana hou, e like me ka hōʻuluʻulu ʻia ma a 2023 replication-pilikia loiloi. ʻAʻole ana nā helu i nā peptides; hoʻopaʻa ʻelua ʻo ka pilikia reproducibility he systemic, ʻaʻole pilikino.
ʻO ka hopena kūpono: ma mua o ka hoʻoholo ʻana i kahi kūʻē, inoa ʻo wai o nā mokuʻāina ʻekolu i ana ʻia kēlā me kēia waihona.
Ka Hoʻolālā ʻana i nā Mea Mana Mana Zinc: He Titration Matrix no ka Uptake and MoA Studies
ʻO kahi hoʻolālā assay peptide uptake defensible e lawe i ʻekolu mau lima, a ʻo ka helu poʻomanaʻo e kapa i ka lima i loaʻa mai ai. ʻO ka liʻiliʻi liʻiliʻi he lima chelated, he lima piha a me ka hoomalu ole; Hoʻokaʻawale ka lima waena ʻehā i ka hōʻailona peptide mai ka ʻaoʻao waena.
|
Ka lima |
Kūlana zinc medium |
ʻO ke kuhikuhi i manaʻo ʻia no ka heluhelu ʻana |
He aha ka hopena null Mea Hana Peptide Paʻa Paʻa ʻo ia hoʻi |
|---|---|---|---|
|
Chelated (TPEN-papa) |
Ua pau ka zinc |
E hoʻohaʻahaʻa i ka internalization inā pili ka zinc |
ʻAʻole pono ka lawe ʻana i ka zinc medium, a i ʻole ka Hoʻopili ʻia ʻo Peptide Synthesis ʻAʻole hoʻopau ʻo chelator i ka wai kūpono |
|
Physiological-serum |
Laina-serum, hana ole ia |
Kūlana kuhikuhi Mea_Peptides |
ʻAʻole hiki ke ʻike ʻia ka hopena i ka zinc physiological |
|
Hoʻohui ʻia ʻo Zn²⁺ ma kahi ʻōlelo ʻia |
Supraphysiological |
ʻOi aku ka nui o ka internalization inā ʻae ʻia ka zinc |
Hoʻopili ka Saturation a i ʻole ka hopena hoʻokūkū i ka pane |
|
Waena-wale |
ʻAʻohe peptide |
Kāpae |
ʻO ka lepili a i ʻole matrix artefact ka mea i hoʻomalu i ka hōʻailona |
No ka palena o luna, ʻO ka pae hoʻonaʻauao i hoʻohana ʻia ma ka hana HepG2-NTCP he 50–100 µM a me 100–150 µM ZnCl₂, me 22.2 mg/kg/lā zinc gluconate no 6 nā lā i loko o ka ʻiole hydrodynamic-injection model (ʻO ka hana antiviral o ka zinc e kū'ē i nā maʻi hepatitis, 2023). Kuhi ʻia kēia mau helu i kahi loiloi hoʻokahi ma mua o nā hale hana kūʻokoʻa, no laila e mālama iā lākou ma ke ʻano he bracket hoʻomaka, ʻaʻole i hoʻopaʻa ʻia ka dose-pane.
ʻŌlelo aʻo: Hoʻopiʻi ʻo Zn²⁺ i nā mea hoʻolaha fluorescent. E koho i nā lepili a me nā kaohi me ia i ka noʻonoʻo ma mua o kou manaʻo ʻana i ka hāʻule ʻana o ka hōʻailona e hōʻemi i ka lawe ʻana.
Hoʻonohonoho ʻana i nā koi mechanism-of-action a puni nā ʻanuʻu Zinc-Dependent
Loaʻa nā haʻawina mechanism-of-action no nā peptides antiviral i ka pilikia ke kau ʻia ka zinc ma ke ala hewa. Hoʻokomo ka ʻikepili i loaʻa ma hope o ke komo ʻana, ʻaʻole ma ka mea hoʻokipa. A 2023 ʻO ka loiloi o ka hana antiviral a zinc hōʻike ʻaʻole i hoʻopilikia ka zinc i ka HBV preS1 paʻa a i ʻole ke komo ʻana i nā pūnaewele hōʻike NTCP., a e hana ana kēlā ʻae ʻana i nā ʻanuʻu hana hou ma hope (Nā palena i ka Microbiology, 2023). Hōʻike maopopo ʻia ka loiloi like ʻaʻole i hōʻike ʻia ke ʻano molekala pololei, no laila, ua kapa ʻia kahi ʻōlelo hoʻopiʻi ʻo MoA i ka ʻanuʻu i uhi ʻia a ʻaʻole i hala ma mua o ia.
He mea nui ia no ka mea ʻokoʻa ke ʻano o ka ʻanuʻu komo. ʻO ka domain preS1 o L-HBsAg ka mea i ʻike ʻia e NTCP, a koi ʻia nā koena NTCP kikoʻī no ia: Hoʻopau kekahi mau hoʻololi i ka paʻa preS1 a me ka maʻi (Mākou et al., ʻO ka maʻi gastroenterology, 2014). Ua ʻike ʻia ka mea loaʻa iā ia ʻo NTCP (SLC10A1), ʻO ia ka HBV a me HDV i hoʻohana ʻia no ke komo ʻana o nā ʻano i loko o nā hepatocytes (ʻO Yan et al., eLife, 2012).
ʻO kahi hana viral pili i ka zinc e hiki ke hoʻolālā ʻia kahi papahana e noho ana ma ke koena pae ma mua o ka loaʻa. Hoʻonohonoho ka motif HBx CCCH i ka zinc ma o C61, C69, C115, C137 a me H139, ʻo ia ke ʻano pahuhopu i wehewehe ʻia e hiki i kahi ʻāpana MoA ke heleuma.
ʻO ka lula hoʻoholo ma hope o kēlā māhele. Inā hoʻokomo ka zinc i ka paʻa, ʻaʻole hiki i ka lima mana zinc ke hoʻoneʻe i ka heluhelu, no ka mea, ʻaʻole pili i ka zinc ka pae e hoʻopilikia ai. E inoa i ka ʻanuʻu e pili ana i ka zinc a ʻaʻole ma mua o ka hoʻolālā ʻana i ka lima.
Hoʻoholo i nā ʻikepili Kūʻē Kūʻē: He Laau Hooholo
ʻO ka hapa nui o nā kū'ē ma waena o ʻelua mau ʻikepili internalization e hoʻoholo i kekahi o nā kumu ʻehā ma mua o ka hoʻoholo ʻana i ka peptide. E hana iā lākou ma ke kaʻina kumukūʻai, no ka mea, ʻo nā wehewehe haʻahaʻa loa ka mea maʻamau.
1. Kūlana zinc medium. Inā hoʻohana kekahi lab i ke kikowaena piha a ʻo kekahi he lima chelated a i hoʻemi ʻia ka serum, ʻAʻole i ana like nā hoʻokolohua ʻelua. E nānā i ka hoʻokumu ʻana ma mua o ka nānā ʻana i ka peptide.
2. Ke kinai ana i ka mea hoike. Hiki ke hāʻule nā heluhelu fluorescence me ka hāʻule ʻole o ka uptake. ʻAʻole ʻokoʻa ka hāʻule ʻana o ka hōʻailona he hopena lawe.
3. Hoʻopaʻa a me ka permeabilisation. ʻO ka mea hana hoʻoponopono e hoʻoneʻe i kāu hōʻailona he kumu i kākau ʻia o nā hopena internalization divergent, a he mea hoololi protocol, ʻaʻole he mea olaola. E holo i ke kelepona ola a me nā lima paʻa i hoʻokahi ʻaoʻao.
4. Mokuʻāina lawe. ʻO ka mokuʻāina ʻo Transporter ma ke ʻano he loli āu i hoʻonohonoho ʻole ai e uhi i ka ZIP-ʻohana endocytosis a me ka degradation, pale ʻana i ka metallothionein, a me ka hāʻawi hou ʻana o ka host-zinc i ka maʻi. ʻO kēia ka lālā kahi i pau ai ka hoʻoponopono zinc intracellular i ke kūlana hope a lilo i wehewehe.
ʻElua kumu hou aʻe e noho ana ma waho o kēlā kauoha a pono ke kapa inoa. ʻO ke ala e hoʻololi ai me ka noʻonoʻo ʻana, ʻo ia hoʻi ka ʻokoʻa ʻokoʻa wale nō e hiki ke hana i ʻelua mau hana "kū'ē".. A he systemic ka pilikia reproducibility, ʻaʻole pilikino: ʻoi aku ma mua o ka hapalua o nā ʻike preclinical i paʻi ʻia ʻaʻole hiki ke hana hou ʻia ma nā lab kūʻokoʻa, no laila, ʻo ka hakakā ma waena o ʻelua mau ʻikepili ka hihia i manaʻo ʻia ma mua o kahi anomaly.
Ka palena pono: ʻAʻole hiki ke hoʻoholo ʻia kekahi mau ʻikepili kūʻē mai ka moʻolelo i paʻi ʻia. Inā ʻaʻohe pepa e hōʻike i ka zinc medium, ʻano hoʻopaʻa, a i ʻole ka ʻōlelo hoʻoili, ʻaʻole e koi ʻia ka ʻōlelo hoʻoholo. E haʻi iā ʻoe i ka mana e holo aʻe, a ʻo ia ka hoʻopuka pono. ʻO ka Polypeptide Synthesis
ʻO ka maikaʻi o nā mea ma ke ʻano he mea pono: Kūʻē, Maʻemaʻe a me Lot-Level palapala
Hele ka counterion me kāu peptide, a he mea hoʻokomo hōʻike ma mua o kahi kikoʻī kūʻai. A 2025 ka nānā ʻana i nā palapala hopena counter-ion e hoʻololi ke koena trifluoroacetate i ka peptide conformation, me ka helix induction ma LL-37 a me ka structural perturbation o pediocin PA-1, a hoʻomaopopo iā ia ma ke ʻano he kumu o ka hana hoʻāʻo hilinaʻi nui (Nā hopena o nā Counter-Ions ma ke ʻano o ka Peptide Structure, Ka hana, and Assays, 2025). Hoʻololi ka counterion i ka conformation, ʻaʻole ka nui wale.
Pono nā lepili maʻemaʻe i ka nānā like. He loiloi hou o 47 loaʻa i ka nui o ka maʻemaʻe maoli o nā hailona ≥98% e HPLC 96.3%, me ka laulā o 92.1–99.4% (Nā hōʻike hōʻike hoʻomaʻemaʻe peptide, 2025). He aha a 98% ua ana maoli ʻia ka lepili 47 he mahele ka hailona, aole he mau.
E mālama i ka pūʻolo analytical ma ke ʻano he ʻāpana o ka moʻolelo hoʻāʻo: kahi laula hoʻomaʻemaʻe HPLC, Hōʻoia ʻike ʻike MS, a me ka sterility a me ka ho'āʻo endotoxin, pili i ka hailona kiko'ī i hoʻohana ʻia.
Hōʻike: Loaʻa i ka MOL Changes kahi hoihoi pāʻoihana i nā kūlana maikaʻi peptide. Kākoʻo kāna synthesis maʻamau i nā māka maʻemaʻe mai ka crude a i 99% ana ʻia e HPLC a me MS, me ka lot-to-lot consistent controlled ma o ka ho'āʻo pinepine ʻana i kēlā me kēia kaʻina hana a me kahi palapala hōʻoia e pili ana i kēlā me kēia kauoha..
Hoʻomaka: ʻO nā ʻanuʻu mua ʻekolu no kahi papahana e paʻa ana i nā ʻikepili kū'ē
E hoʻomaka me ka waena, ʻaʻole me kahi hoʻokolohua hou. Huki i ka hoʻohālikelike waena a me ka ʻāpana serum no kēlā me kēia ʻikepili i ke kūʻē ʻana a waiho iā lākou i kēlā me kēia ʻaoʻao. ʻAʻohe kumu kūʻai, ʻaʻole pono ka manawa hoʻomaha, a hoʻoholo i ka māhele koʻikoʻi o nā hihia nona iho, no ka mea, ua lawa ka hoʻololi ʻana i ka nui o ka serum a i ʻole ka hoʻololi ʻole ʻia o ka ʻikepili trace-metal e hoʻoneʻe i kahi heluhelu internalization ma waena o nā holo..
ʻO ka ʻanuʻu ʻelua e hoʻōki i ka hana hou ʻana i ke kūlana kumu. Hoʻohui i hoʻokahi lima chelated a me kekahi lima piha i ka holo aʻe, me ka hoʻohana ʻana i ka matrix titration i kūkulu ʻia no ka papahana, a holo iā lākou me ke ʻano āu e hana hou nei. ʻO ka hana hou ʻana i kahi kūlana hoʻokahi e haʻi iā ʻoe inā paʻa ka hopena; ʻAʻole ia e haʻi iā ʻoe i ke ʻano o ke ana. ʻElua mau lima e hoʻopaʻa ana i ka hoʻololi zinc e hoʻohuli i kahi kūʻē i mea hoʻohālikelike.
ʻO ka ʻanuʻu ʻekolu e hoʻoponopono i ka hierarchy heluhelu ma mua o ka heluhelu ʻana o ka pā aʻe. E hōʻike i ka hopena ma ke ʻano he mokuʻāina, pili i ka ʻili, i loko a hoʻohaʻahaʻa paha, ma mua o hoʻokahi helu internalization. ʻO kēlā hoʻololi wale nō ka mea e pale ai i ka hōʻiliʻili ʻikepili aʻe mai ka hōʻea ʻana i ke ʻano hiki ʻole ke hoʻonā ʻia e like me ka mea hope, a hiki ke hoʻohana hou ʻia ka hoʻolālā peptide uptake assay ma waena o nā papahana ma mua o ke kūkulu hou ʻana i kēlā me kēia manawa i ʻike ʻia kahi kūʻē..
ʻEkolu kapuaʻi, ʻaʻohe mea kani hou, a hiki ke unuhi ʻia ka ʻikepili aʻe.
Nīnau pinepine
ʻO ka zinc kahi mea pale NTCP?
ʻAʻole. Hana ʻo Zinc ma hope o ke komo ʻana, ʻaʻole ma ka mea hoʻokipa. A 2023 ʻO ka loiloi o ka zinc i loko o ka maʻi hepatitis B a me D ke kau nei i kona hopena pale i nā pae hope o ke komo ʻana ma mua o ka NTCP-mediated viral binding., no laila, ʻaʻole i hoʻopili ka mea lawe i ka zinc-sensitive phenotype i ka uptake assay (2023 ka nānā ʻana i ka zinc ma ka maʻi HBV/HDV). E mālama i ka pale ʻana i ka mea hoʻokipa a me ka pale ʻana ma hope o ke komo ʻana ma ke ʻano he kuhiakau kaʻawale me nā mana ʻokoʻa.
ʻO ka zinc-finger antivirals a me ka zinc-ion biology ka mea like?
ʻAʻole. ʻO kahi pūmua antiviral zinc-finger kahi mea hoʻopaʻa hoʻokipa e hoʻopaʻa ai i ka RNA viral; ʻO ka hoʻoponopono zinc intracellular he ʻano metala-ion e hoʻololi i ka peptide a me ka ʻano protein. Hoʻokaʻawale lāua i kahi huaʻōlelo, ʻaʻole he mīkini, a ʻo kahi pepa e pili ana i kekahi e haʻi ʻole iā ʻoe e pili ana i kekahi.
ʻO ka hoʻihoʻi ʻana o ka chelation i ka lawe ʻana he mea pili ʻole ka zinc?
ʻAʻole. ʻO ia ka mea i loaʻa i ka assay kahi zinc setpoint. ʻO ka wehe ʻana i ka zinc ua hoʻoneʻe i ka heluhelu, ʻo ia ka mea hōʻike e pane ana ka ʻōnaehana i ka zinc, ʻAʻole kēlā zinc he mea hana e holoi ʻia.
Pehea e pono ai ka peptide:Hōʻike ʻia ka Zn stoichiometry?
E hōʻike i ka ratio molar, ka haku mele, a me ke kauoha o ka hoohui, no ka mea, hoʻololi nā mea ʻekolu i ka ratio i ana ʻia. E hōʻike i ka counterion a me ka pH, a hāʻawi i ka ratio ma ke ʻano he laulima me kāna ʻano ana ma mua o ka helu hoʻokahi.
ʻO ke komo ʻana o ka picomolar bulevirtide kahi hōʻailona kūpono no kahi peptide hou?
Me ka helu ʻelua wale nō i hoʻopili ʻia. Kāohi ʻo Bulevirtide i ke komo ʻana o HBV a me HDV me kahi IC50 o 140 pM i nā hepatocytes kanaka mua a me nā pūnaewele HepaRG, oiai ka like ole nanomolar taurocholate inhibition haawi i ka IC50 o 195 nM (95% CI 174–218 nM) (Nature Communications, 2024). E kuhikuhi i nā mea ʻelua a ʻaʻole paha.
He aha nā palapala hoʻoponopono e pili ana?
ʻO Bulevirtide wale nō ka NTCP-targeting entry inhibitor, no laila ʻo ka loiloi ʻana o ka EMA o Hepcludex ka kikoʻī paʻi kokoke loa no kēia papa (EMA Hepcludex EPAR). No ka hana kālailai, I Q2(R2) hoʻomalu i ka hōʻoia, USP <71> a <85> uhi i ka sterility a me ka endotoxin, a me nā loina ALCOA o MHRA e hoʻomalu i ka pono o ka ʻikepili.
Ka hopena
ʻO ka biology Zinc i ka hoʻomohala ʻana i ka peptide e pili ana i ka maʻi hepatitis he mea liʻiliʻi ia i kahi hana hou ma mua o kahi ʻāpana i nalowale: ʻO ka hapa nui o nā hana hoʻopiʻi, ʻaʻole i hōʻike ʻia ke kūlana zinc o ka medium assay a me nā cell, a ʻo ka haʻalele ʻana ʻo ia ka mea e waiho ai i ka ʻikepili i ʻike ʻole ʻia ke ana ʻia ma lalo o nā kūlana like ʻole. ʻO ka hōʻike ʻana e hoʻohuli iā lākou i mau mea like.
ʻO nā mea hana ʻehā i loko o kēia alakaʻi e hana like ma mua o ka hoʻokaʻawale. Hoʻoponopono ka matrix titration i ka mea i loko o ke kikowaena. Hoʻokaʻawale kahi hierarchy heluhelu i ka mea e ana maoli ai ka hōʻailona mai ka mea i manaʻo ʻia e ana. ʻO ka palapala ʻana i nā ʻōlelo hoʻopiʻi hana ma luna o nā ʻanuʻu pili i ka zinc e hōʻike ana i kahi i hilinaʻi ʻia ai ka hopena i kahi manaʻo i ʻōlelo ʻole ʻia.. A laila haʻi ka lāʻau hoʻoholo iā ʻoe i kahi o ʻelua mau ʻikepili paio e hilinaʻi ai, a i ka wa i pane pololei ole ai.
ʻO ke kuhikuhi o ka huakaʻi e pili ana i ka hōʻike piha: kūlana metala, Manaʻo nui ʻia nā lima mana a me nā palapala pae ʻāina ma ke ʻano he ʻāpana o ke ʻano ma mua o nā kikoʻī koho. E maʻalahi ka wehewehe hou ʻana o nā polokalamu i kākau iā lākou i kēia manawa.
Inā ʻoe e paʻa ana i ka ʻikepili internalization kū'ē a makemake i kahi heluhelu kūʻokoʻa ma ka ʻaoʻao analytical, e kamaʻilio me kahi loea loea e pili ana i kāu kaʻina a me nā kūlana assay ma hope o ia.
Kūkākūkā kēia ʻatikala i ke ʻano noiʻi in vitro wale nō. ʻAʻole ia he alakaʻi lapaʻau a diagnostic paha. E nīnau i kekahi kauka lapaʻau kūpono ma mua o ka hoʻoholo ʻana i ka lāʻau lapaʻau.
